Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression to chronic kidney disease (CKD).

拜耳在英国推出了数字患者支持包，旨在帮助2型糖尿病患者照顾肾脏健康，避免进展为慢性肾病（CKD）。

The package, dubbed My Kidney Assistant, offers personalised health information and data recording features and is being rolled out initially to a cohort of diabetes patients in England, including some who have already been diagnosed with CKD.

该软件包被称为我的肾脏助理，提供个性化的健康信息和数据记录功能，最初正在英格兰的一组糖尿病患者中推出，其中包括一些已被诊断患有CKD的患者。

Kidney damage is a well-recognised complication of diabetes, with around 40% of patients eventually going on to develop CKD. That also raises their risk of cardiovascular disease, according to Bayer Digital Health UK & Ireland, a newly established business unit.

肾脏损害是公认的糖尿病并发症，约40%的患者最终会发展为CKD。根据新成立的业务部门拜耳数字健康英国和爱尔兰的说法，这也增加了他们患心血管疾病的风险。

My Kidney Assistant allows users to log health data like blood pressure, cholesterol, and blood sugar levels, as well as test results and how well they are adhering to drug treatments. They can also set personal goals – including weight loss, activity levels, and alcohol reduction – and get reminders to take their medication..

我的肾脏助手允许用户记录血压，胆固醇和血糖水平等健康数据，以及测试结果以及他们对药物治疗的依从性。他们还可以设定个人目标-包括减肥，活动水平和减少酒精-并提醒他们服药。。

The tool – developed in collaboration with patient engagement specialist Cognitant Group – also provides advice on other health measures such as stopping smoking, diet planning and taking regular exercise.

该工具-与患者参与专家认知小组合作开发-还提供有关其他健康措施的建议，例如戒烟，饮食计划和定期锻炼。

The expectation is that patients using the app will be able to understand and manage their risk of CKD more effectively. Meanwhile, for those already diagnosed with CKD, Bayer hopes that improved self-management and treatment adherence will help to reduce disease progression.

期望使用该应用程序的患者能够更有效地理解和管理他们的CKD风险。同时，对于那些已经诊断为CKD的患者，拜耳希望改善自我管理和治疗依从性将有助于减少疾病进展。

According to Cognitant’s co-founder and chief executive Dr Tim Ringrose, studies have shown that around 61% of England’s working-age population find health information difficult to understand, and between 40% and 80% of information given during doctor appointments is forgotten immediately.

根据Cognitant的联合创始人兼首席执行官Tim Ringrose博士的研究表明，英格兰约61%的工作年龄人口发现健康信息难以理解，医生预约期间提供的信息中有40%至80%立即被遗忘。

“My Kidney Assistant is a support package that’s been specially created to fulfil an important need,” he said. “It is an example of how multiple stakeholders in the healthcare ecosystem can collaborate to create impactful digital support programmes, pooling their expertise to produce a tool that really makes a difference to…engagement and health outcomes.”.

他说：“我的肾脏助理是专门为满足重要需求而创建的支持包。“这是医疗保健生态系统中多个利益相关者如何合作创建有影响力的数字支持计划，汇集他们的专业知识以产生真正对…参与和健康结果产生影响的工具的一个例子。”。

Earlier this year, Bayer secured approval from NICE for NHS use of recently-approved therapy Kerendia (finerenone) as an add-on to standard care for the treatment of adults with stage 3 and 4 CKD associated with type 2 diabetes.

今年早些时候，拜耳获得了NICE批准NHS使用最近批准的Kerendia（finerenone）疗法作为治疗与2型糖尿病相关的3期和4期CKD成人的标准护理的附加物。

Bayer has made digital health a core part of its offering to patients, alongside the prescription medicines it brings to market as well as consumer health products, and for a number of years has run a digital health incubation scheme to support startups in the category.

拜耳已经将数字健康作为其向患者提供的核心部分，以及它推向市场的处方药以及消费者健康产品，并且多年来一直运行数字健康孵化计划以支持该类别的初创企业。

“We look forward to working with our partners to better understand the value added from My Kidney Assistant and also explore how it can be enhanced to provide even greater functionality and support those at risk of kidney disease, allowing for even earlier identification and prevention of complications,” commented Nigel Brokenshire, head of Bayer Digital Healthcare UK & Ireland..

“我们期待与我们的合作伙伴合作，更好地了解我的肾脏助理所增加的价值，并探讨如何增强它以提供更大的功能并支持有肾脏疾病风险的人，从而更早地识别和预防并发症，”英国和爱尔兰拜耳数字医疗保健公司负责人Nigel Brokenshire评论道。。